Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, double-dummy, placebo-controlled, five-way crossover study to assess the effects of single oral doses of SB-681323 (7.5 mg and 25 mg) and prednisolone (10 mg and 30 mg) on biomarkers in induced sputum and blood in COPD [chronic obstructive pulmonary disease] patients.

Next Previous
X
Search
Trial Profile

A randomised, double-blind, double-dummy, placebo-controlled, five-way crossover study to assess the effects of single oral doses of SB-681323 (7.5 mg and 25 mg) and prednisolone (10 mg and 30 mg) on biomarkers in induced sputum and blood in COPD [chronic obstructive pulmonary disease] patients.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dilmapimod (Primary) ; Prednisolone
  • Indications Chronic obstructive pulmonary disease
  • Focus Biomarker; Pharmacodynamics
  • Sponsors GSK

    • Most Recent Events

    • 15 Mar 2012 Actual end date (April 2006) added as reported by ClinicalTrials.gov.
    • 01 Jan 2010 Results have been reported in the Journal of Clinical Pharmacology.
    • 24 Mar 2009 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top